The major oncogenic unit in HER2-positive breast cancer appears to be a heterodimer between the HER2 and epidermal growth factor receptor-3 (HER3) proteins, where HER3 functions as a necessary dimerization partner for HER2 to achieve full oncogenic signaling potential [131]. This evidence concerns the gene ERBB3 and breast carcinoma.